Flow cytometric analysis of benign and malignant tumors

$2,322,568ZICFY2025CANIH

Division Of Clinical Sciences - Nci

Investigators

Linked publications, trials & patents

Paper 38899877 Paper 38813719 Paper 38376944 Paper 38155568 Paper 35605184 Paper 35534047 Paper 34920453 Paper 33653216 Paper 33554406 Paper 33211080 Paper 32830879 Paper 32202637 Paper 32109194 Paper 32040482 Paper 31981407 Paper 31665200 Paper 30212602 Paper 30104242 Paper 29728700 Paper 29487070 Paper 29483101 Paper 28888074 Paper 28540748 Paper 28475275 Paper 28074063 Paper 27556705 Paper 27363814 Paper 26780351 Paper 26660519 Paper 26350263 Paper 26337493 Paper 26202864 Paper 25907102 Paper 25622976 Paper 25555420 Paper 25319501 Paper 25304612 Paper 25263319 Paper 25132630 Paper 24578489 Paper 24462038 Paper 24419126 Paper 24225748 Paper 23929839 Paper 23915224 Paper 23689118 Paper 23674507 Paper 23520331 Paper 23347903 Paper 23311294 Paper 23243285 Paper 22473867 Paper 22431420 Paper 22289893 Paper 22261447 Paper 22160384 Paper 21745173 Paper 21599609 Paper 21571962 Paper 21508125 Paper 21504292 Paper 21472850 Paper 21472849 Paper 21463128 Paper 21368287 Paper 21232656 Paper 21116989 Paper 20956803 Paper 20940416 Paper 20872890 Paper 20739953 Paper 20668228 Paper 20528877 Paper 20447965 Paper 20231613 Paper 20215554 Paper 20068111 Paper 20020522 Paper 19918335 Paper 19826128 Paper 19745070 Paper 19555363 Paper 19414673 Paper 19327830 Paper 19293260 Paper 18770650 Paper 18671252 Paper 18431797 Paper 17895404 Paper 16675574 Paper 16649227 Paper 16311729 Paper 16044437 Paper 15973700 Paper 15786509 Paper 15358629 Paper 12949961 Paper 12599176 Paper 12595313 Paper 12579991

Abstract

The Flow Cytometry Unit provides comprehensive clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies, and body fluids for the diagnosis and monitoring of hematolymphoid neoplasia in NIH patients. The laboratory supports numerous NCI clinical protocols by offering diagnostic testing for leukemia and lymphoma, either as endpoint evaluations or for determining patient eligibility. A major focus of the Unit is the detection of minimal residual disease (MRD) with high sensitivity, down to levels 10^-5. In addition, the laboratory performs specialized assays to measure tumor cell characteristics required for protocol enrollment, many of which are not available through commercial or academic laboratories. Considerable effort is devoted to the development and validation of these unique, protocol-specific tests. The Flow Cytometry Unit also plays an active role in educating NIH staff and the broader medical community on the appropriate application of flow cytometry in clinical practice.

View original record on NIH RePORTER →